ABSTRACT
Corneal collagen crosslinking (CXL) is a commonly used minimally invasive surgical technique to prevent the progression of corneal ectasias, such as keratoconus. Unfortunately, riboflavin/UV-A light-based CXL procedures have not been successfully applied to all patients, and result in frequent complications, such as corneal haze and endothelial damage. We propose a new method for corneal crosslinking by using a Ruthenium (Ru) based water-soluble photoinitiator and visible light (430 nm). Tris(bipyridine)ruthenium(II) ([Ru(bpy)3]2+) and sodium persulfate (SPS) mixture covalently crosslinks free tyrosine, histidine, and lysine groups under visible light (400-450 nm), which prevents UV-A light-induced cytotoxicity in an efficient and time saving collagen crosslinking procedure. In this study, we investigated the effects of the Ru/visible blue light procedure on the viability and toxicity of human corneal epithelium, limbal, and stromal cells. Then bovine corneas crosslinked with ruthenium mixture and visible light were characterized, and their biomechanical properties were compared with the customized riboflavin/UV-A crosslinking approach in the clinics. Crosslinked corneas with a ruthenium-based CXL approach showed significantly higher young's modulus compared to riboflavin/UV-A light-based method applied to corneas. In addition, crosslinked corneas with both methods were characterized to evaluate the hydrodynamic behavior, optical transparency, and enzymatic resistance. In all biomechanical, biochemical, and optical tests used here, corneas that were crosslinked with ruthenium-based approach demonstrated better results than that of corneas crosslinked with riboflavin/ UV-A. This study is promising to be translated into a non-surgical therapy for all ectatic corneal pathologies as a result of mild conditions introduced here with visible light exposure and a nontoxic ruthenium-based photoinitiator to the cornea. STATEMENT OF SIGNIFICANCE: Keratoconus, one of the most frequent corneal diseases, could be treated with riboflavin and ultraviolet light-based photo-crosslinking application to the cornea of the patients. Unfortunately, this method has irreversible side effects and cannot be applied to all keratoconus patients. In this study, we exploited the photoactivation behavior of an organoruthenium compound to achieve corneal crosslinking. Ruthenium-based organic complex under visible light demonstrated significantly better biocompatibility and superior biomechanical results than riboflavin and ultraviolet light application. This study promises to translate into a new fast, efficient non-surgical therapy option for all ectatic corneal pathologies.
Subject(s)
Keratoconus , Photochemotherapy , Ruthenium , Animals , Cattle , Collagen/pharmacology , Cornea/pathology , Cross-Linking Reagents/pharmacology , Humans , Keratoconus/drug therapy , Keratoconus/pathology , Photosensitizing Agents/pharmacology , Photosensitizing Agents/therapeutic use , Riboflavin/pharmacology , Ruthenium/pharmacology , Ultraviolet RaysABSTRACT
Keratoconus (KC) is a common corneal ectatic disease that affects 1:500-1:2000 people worldwide and is associated with a progressive thinning of the corneal stroma that may lead to severe astigmatism and visual deficits. Riboflavin-mediated collagen crosslinking currently remains the only approved treatment to halt progressive corneal thinning associated with KC by improving the biomechanical properties of the stroma. Treatments designed to increase collagen deposition by resident corneal stromal keratocytes remain elusive. In this study, we evaluated the effects of arginine supplementation on steady-state levels of arginine and arginine-related metabolites (e.g., ornithine, proline, hydroxyproline, spermidine, and putrescine) and collagen protein expression by primary human corneal fibroblasts isolated from KC and non-KC (healthy) corneas and cultured in an established 3D in vitro model. We identified lower cytoplasmic arginine and spermidine levels in KC-derived constructs compared to healthy controls, which corresponded with overall higher gene expression of arginase. Arginine supplementation led to a robust increase in cytoplasmic arginine, ornithine, and spermidine levels in controls only and a significant increase in collagen type I secretion in KC-derived constructs. Further studies evaluating safety and efficacy of arginine supplementation are required to elucidate the potential therapeutic applications of modulating collagen deposition in the context of KC.
Subject(s)
Arginine/pharmacology , Extracellular Matrix/metabolism , Keratoconus/pathology , Up-Regulation/drug effects , Arginase/metabolism , Arginine/metabolism , Arginine/therapeutic use , Case-Control Studies , Cell Culture Techniques , Cells, Cultured , Collagen/metabolism , Collagen Type I/metabolism , Cornea/cytology , Cornea/metabolism , Fibroblasts/cytology , Fibroblasts/drug effects , Fibroblasts/metabolism , Humans , Keratoconus/drug therapy , Keratoconus/metabolism , Nitric Oxide Synthase/metabolism , Ornithine/metabolism , Spermidine/metabolismABSTRACT
PURPOSE: Keratoconus (KC) is a disease characterized by thinning and deformation of the cornea, but its etiology remains unknown. Seventy percent of the corneal stroma consists of collagen, which is composed of three intertwined polypeptide chains with glycine-hydroxyproline-proline repeats along their sequence. Arginase is a cytoplasmatic enzyme and catalyzes the conversion of arginine to urea and ornithine, which serves as a precursor for the endogenous synthesis of proline and hydroxyproline. The purpose of this study was to analyze arginase activity, as well as collagen and urea formation in normal and KC-keratocytes and to determine the impact of urea on keratocyte viability and proliferation in vitro. METHODS: Primary human keratocytes were isolated by digestion in collagenase (1.0 mg/mL) from surgically removed corneas of eight keratoconus patients and eight normal human corneal buttons and cultured in DMEM/Ham's F12 medium supplemented with 5 % fetal calf serum. Arginase activity and urea concentration were measured in cell-lysates, hydroxyproline concentration in supernatant of cultured keratocytes using colorimetric assay. Cell viability and cell proliferation of cultured keratocytes were assessed after treatment with urea at concentrations up to10 mM for 24 h using assays for metabolic activity and DNA replication. RESULTS: Arginase activity and urea concentration in KC-keratocytes decreased by about 50 % compared to normal keratocytes (p = 0.003 and p = 0.008). Hydroxyproline synthesized by cultured KC-keratocytes was also approximately 50 % less compared to normal keratocytes (p = 0.02) and this difference decreased following treatment with 5.0 or 10.0 mM urea (p = 0.02; 0.03), without any change in cell viability (p > 0.09). However, the urea treatment increased modestly (by 20 %) the proliferation rate of KC-keratocytes (p = 0.04; 0.04; 0.04), without any effect on normal cultured keratocytes (p > 0.09). CONCLUSIONS: We identified suppressed arginase activity in the metabolic program of cultured keratoconus keratocytes. The level of urea, as one product of the enzyme arginase was also decreased. This results in impaired collagen synthesis, evidenced in the culture by reduced hydroxyproline concentration. In addition, our data showed that the other product of the arginase reaction, urea supports the proliferation of KC-keratocytes, without changes in their viability. The metabolic reprogramming of keratoconus keratocytes and its impact on development of a clinically detectable keratoconus disease has to be further analyzed.
Subject(s)
Arginase/metabolism , Cornea/metabolism , Corneal Keratocytes/metabolism , Hydroxyproline/metabolism , Keratoconus/metabolism , Urea/metabolism , Apoptosis , Biomarkers/metabolism , Blotting, Western , Cell Proliferation , Cell Survival , Cells, Cultured , Cornea/pathology , Corneal Keratocytes/pathology , Humans , Keratoconus/pathologyABSTRACT
PURPOSE: The purpose of this study was to determine the impact of cross-linking (CXL) on viability, apoptosis, proliferation, activation, and cytokine secretion of human keratoconus (KC) keratocytes, in vitro. METHODS: Primary KC keratocytes were cultured in DMEM/Ham's F12 medium supplemented with 10% FCS and underwent UVA illumination (370 nm, 2 J/cm(2)) during exposure to 0.1% riboflavin and 20% Dextran in PBS. Twenty-four hours after CXL, viability was assessed using Alamar blue assay; apoptosis using APO-DIRECT Kit; proliferation using ELISA-BrdU kit; and CD34 and alpha-smooth muscle actin (α-SMA) expression using flow cytometry. Five and 24 hours after CXL, FGFb, HGF, TGFß1, VEGF, KGF, IL-1ß, IL-6, and IL-8 secretion was measured using enzyme-linked-immunoabsorbent assay (ELISA). RESULTS: Following CXL, cell viability and proliferation decreased (P < 0.05; P = 0.009), the percentage of apoptotic keratocytes increased (P < 0.05) significantly, and CD34 and α-SMA expression remained unchanged (P > 0.06). Five hours after CXL, FGFb secretion increased significantly (P = 0.037); however no other cytokine secretion differed significantly from controls after 5 or 24 hours (P > 0.12). CONCLUSIONS: Cross-linking decreases viability, triggers apoptosis, and inhibits proliferation, without an impact on multipotent hematopoietic stem cell transformation and myofibroblastic transformation of KC keratocytes. CXL triggers FGFb secretion of KC keratocytes transiently (5 hours), normalizing after 24 hours.
Subject(s)
Apoptosis/drug effects , Cell Proliferation/drug effects , Cell Survival/drug effects , Corneal Keratocytes/drug effects , Cross-Linking Reagents/pharmacology , Cytokines/metabolism , Keratoconus/pathology , Actins/metabolism , Antigens, CD34/metabolism , Carrier Proteins/metabolism , Cells, Cultured , Corneal Keratocytes/metabolism , Corneal Keratocytes/pathology , Flow Cytometry/methods , Humans , Intercellular Signaling Peptides and Proteins/metabolism , Keratoconus/metabolism , Photosensitizing Agents/pharmacology , Riboflavin/pharmacology , Ultraviolet RaysABSTRACT
Keratoconus (KC) is a complex thinning disease of the cornea that often requires transplantation. The underlying pathogenic molecular changes in this disease are poorly understood. Earlier studies reported oxidative stress, metabolic dysfunctions and accelerated death of stromal keratocytes in keratoconus (KC) patients. Utilizing mass spectrometry we found reduced stromal extracellular matrix (ECM) proteins in KC, suggesting ECM-regulatory changes that may be due to altered TGFß signals. Here we investigated properties of stromal cells from donor (DN) and KC corneas grown as fibroblasts in serum containing DMEM: F12 or in serum-free medium containing insulin, transferrin, selenium (ITS). Phosphorylation of SMAD2/3 of the canonical TGFß pathway, was high in serum-starved DN and KC fibroblast protein extracts, but pSMAD1/5/8 low at base line, was induced within 30 minutes of TGFß1 stimulation, more so in KC than DN, suggesting a novel TGFß1-SMAD1/5/8 axis in the cornea, that may be altered in KC. The serine/threonine kinases AKT, known to regulate proliferation, survival and biosynthetic activities of cells, were poorly activated in KC fibroblasts in high glucose media. Concordantly, alcohol dehydrogenase 1 (ADH1), an indicator of increased glucose uptake and metabolism, was reduced in KC compared to DN fibroblasts. By contrast, in low glucose (5.5 mM, normoglycemic) serum-free DMEM and ITS, cell survival and pAKT levels were comparable in KC and DN cells. Therefore, high glucose combined with serum-deprivation presents some cellular stress difficult to overcome by the KC stromal cells. Our study provides molecular insights into AKT and TGFß signal changes in KC, and a mechanism for functional studies of stromal cells from KC corneas.
Subject(s)
Cell Culture Techniques , Corneal Stroma/cytology , Corneal Stroma/metabolism , Insulin/pharmacology , Keratoconus/pathology , Transforming Growth Factor beta/metabolism , Cell Proliferation , Cell Survival , Cells, Cultured , Corneal Stroma/pathology , Extracellular Matrix Proteins/metabolism , Fibroblasts/metabolism , Gene Expression Regulation , Humans , Keratoconus/metabolism , Mass Spectrometry , Selenium/pharmacology , Signal Transduction , Tissue Donors , Transferrin/pharmacologyABSTRACT
BACKGROUND: Keratoconus manifests as a conical protrusion of the cornea and is characterised by stromal thinning. This causes debilitating visual impairment which may necessitate corneal transplantation. Therapeutic targets related to disease mechanisms are currently lacking, as the pathobiology remains unclear. Many pathological features may be manifestations of defects in wound healing and reactive oxygen species (ROS)-associated functions. In a wide range of tissue and cell types, antioxidant exposure has beneficial effects on both of these pathways. This study investigated the effect of treatment with the antioxidant riboflavin on wound healing and ROS-associated functions in keratoconus. METHODS: Stromal cells were isolated from human central keratoconic (n = 3) and normal (n = 3) corneas. Total RNA was extracted and reverse-transcribed into complementary DNA. The gene expression of 22 genes involved in repair (eight normal and four repair-type extracellular matrix constituents) and ROS-associated processes (eight antioxidants and two ROS-synthesising oxidases) was quantified using quantitative polymerase chain reaction. This was also performed on keratoconic stromal cells treated in vitro with riboflavin (n = 3). RESULTS: In stromal cells from untreated keratoconic corneas (compared with untreated normal corneas), there was an up-regulation of 7/12 extracellular matrix elements. Four of eight antioxidants and two of two oxidases were also increased. In treated keratoconic corneas (compared with untreated keratoconic corneas), six out of eight normal extracellular matrix constituents were up-regulated and two of four repair-type molecules were reduced. An increase was also observed in seven out of eight antioxidants and there was a diminution in two out of two oxidases. CONCLUSION: Riboflavin encourages the synthesis of a normal extracellular matrix and reduces reactive oxygen species levels in keratoconus. This supports the occurrence of wound healing and ROS-associated abnormalities in keratoconus. By targeting the causative disease mechanisms, riboflavin may have therapeutic potential in the clinical management of keratoconus.
Subject(s)
Corneal Stroma/metabolism , Extracellular Matrix Proteins/genetics , Gene Expression Regulation/drug effects , Keratoconus/genetics , RNA/genetics , Riboflavin/therapeutic use , Corneal Stroma/drug effects , Corneal Stroma/pathology , Extracellular Matrix Proteins/biosynthesis , Humans , Keratoconus/metabolism , Keratoconus/pathology , Oxidative Stress/drug effects , Oxidative Stress/genetics , Polymerase Chain Reaction , Reactive Oxygen Species/metabolism , Vitamin B Complex/therapeutic useABSTRACT
INTRODUCTION: Keratoconus (KC) is an ectatic disorder characterized by the progressive thinning and scarring of central cornea as a consequence of structural and/or compositional anomalies, although the exact etiology is largely unknown. The resultant conical protrusion of the cornea causes significant irregular astigmatism, myopia and visual impairment. AREAS COVERED: This paper will review the biochemical factors involved in the multifactorial pathogenesis of KC and the possible emerging role of inflammation in this process. Additionally, the authors discuss the development of new corneal collagen crosslinking (CCL) protocols using hypoosmolar riboflavin or transepithelial approaches with respect to the associated toxicities at the cellular level. EXPERT OPINION: Long-term consequences of standard and new emerging CCL protocols are still being studied; hence, pharmacokinetic considerations and related potential toxicities are important to consider. CCL sequentially combined with other modalities, specifically intrastromal corneal ring segments and photorefractive keratectomy can optimize the visual rehabilitation of KC patients. As we come to further understand CCL and its pharmacokinetic effects, additional indications for CCL may be discovered especially for those patients who are not suitable candidates for keratoplasty. Randomized control trials evaluating the efficacy of CCL for applications beyond halting KC disease progression are warranted.
Subject(s)
Collagen/pharmacokinetics , Keratoconus/drug therapy , Riboflavin/pharmacokinetics , Animals , Apoptosis/radiation effects , Benzalkonium Compounds/adverse effects , Cornea/drug effects , Cornea/pathology , Cornea/radiation effects , Disease Models, Animal , Drug Evaluation, Preclinical , Epithelial Cells/cytology , Epithelial Cells/radiation effects , Humans , Inflammation/drug therapy , Inflammation/pathology , Interleukin-6/metabolism , Keratoconus/pathology , Randomized Controlled Trials as Topic , Signal Transduction , Ultraviolet Rays/adverse effectsABSTRACT
PURPOSE: This was a qualitative investigation of corneal microstructural modifications in keratoconic patients undergoing experimental transepithelial crosslinking (TE CXL). METHODS: Ten patients with keratoconus intolerant to gas-permeable rigid contact lenses were enrolled. Corneal thickness was in the range 350-390 µm at the thinnest point measured by Visante AC optical coherence tomography system (Zeiss, Jena, Germany). All patients underwent TE CXL with 0.1% riboflavin-15% dextran solution supplemented with TRIS plus sodium EDTA (Ricrolin TE, Sooft Italia) according to Siena protocol. In vivo Heidelberg retinal tomograph II laser scanning confocal analysis (Rostock Cornea Module, Heidelberg, Germany) was performed with the following follow-up: preoperative and postoperative assessments at 1, 3, and 6 months. The following morphologic parameters were evaluated: epithelium, subepithelial, and anterior stroma nerve plexi, keratocytes apoptosis, stromal changes, and the endothelium. RESULTS: After TE CXL, epithelial cells showed apoptosis, with mosaic alterations gradually disappearing. Keratocytes apoptosis was variable, superficial, and uneven, with a maximum depth of penetration at about 140 µm, measured from the surface of epithelium. Treatment respected subepithelial and stromal nerves that did not disappear. No variation in cell count or endothelial mosaic was observed. CONCLUSIONS: In vivo confocal analysis of corneal modifications induced by TE CXL showed a limited apoptotic affect of this treatment, about one-third of classic epi-off crosslinking procedure. The TE CXL respected sub-basal and anterior stroma nerve fibers, resulting safe for corneal endothelium. According to limited penetration, its mid- to long-term efficacy needs to be determined in different clinical settings related to patient age and keratoconus progression.
Subject(s)
Collagen/metabolism , Corneal Stroma/pathology , Cross-Linking Reagents/metabolism , Keratoconus/pathology , Microscopy, Confocal , Photosensitizing Agents/therapeutic use , Apoptosis , Corneal Keratocytes/pathology , Corneal Stroma/innervation , Corneal Stroma/metabolism , Diagnostic Techniques, Ophthalmological , Epithelium, Corneal/metabolism , Humans , Keratoconus/drug therapy , Keratoconus/metabolism , Ophthalmic Nerve/pathology , Riboflavin/therapeutic use , Ultraviolet RaysABSTRACT
The observational case describes bilateral recurrent keratoconus in corneal transplants performed in a patient with self-induced keratoconus secondary to compulsive eye rubbing. Slitlamp findings demonstrated corneal stromal thinning and scarring in the patient's right eye and temporal corneal hydrops in his left eye. Videokeratography of the right eye confirmed the presence of corneal steepening and irregular astigmatism, consistent with the diagnosis of keratoconus involving each transplant. Together with the history of ongoing compulsive eye rubbing, these findings support the concept that chronic mechanical trauma to the cornea may contribute to the development of keratoconus.
Subject(s)
Compulsive Behavior/complications , Corneal Transplantation , Eye , Keratoconus/etiology , Keratoconus/surgery , Massage/adverse effects , Cornea/pathology , Corneal Topography , Humans , Keratoconus/pathology , Male , Middle Aged , RecurrenceABSTRACT
PURPOSE: To report a case of unilateral keratoconus in a 7- year-old female, secondary to chronic persistent eye-rubbing in the absence of any systemic condition. DESIGN: Observational case report. METHODS: In the case of this child, no organic cause was found to explain the onset of keratoconus other than persistent eye-rubbing in the affected eye. RESULTS: Nocturnal eye padding was instigated and the condition stabilized. She was reviewed over a 2-year period of follow-up. CONCLUSIONS: Eye-rubbing has been implicated in the pathogenesis of keratoconus. Eye-rubbing is also often a feature of a number of conditions linked to keratoconus such as Down syndrome, atopic keratoconjunctivitis, mental retardation, and Lebers' congenital amaurosis. There are a number of reports linking eye-rubbing and keratoconus in children, typically in relation to these conditions. However, in this case the keratoconus was secondary to chronic and persistent eye-rubbing in a healthy child.
Subject(s)
Eye , Keratoconus/etiology , Massage/adverse effects , Child , Female , Humans , Keratoconus/pathologyABSTRACT
I suggest that the location of the cone in keratoconus is most often located in the paracentral inferonasal quadrant of the cornea due to the presence of the most senile epithelial cells in this location. These cells may be more vulnerable than younger epithelial cells to the chronic subtle trauma of eyelid rubbing and may be more prone to release enzymes that thin the cornea.